Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Saved in:
| Title: | Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. |
|---|---|
| Authors: | Sena LA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Fountain J; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Isaacsson Velho P; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Lim SJ; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Wang H; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Nizialek E; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Rathi N; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Nussenzveig R; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Maughan BL; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Velez MG; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA., Ashkar R; Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA., Larson AC; Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA., Pritchard CC; Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA., Adra N; Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA., Bryce AH; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA., Agarwal N; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Pardoll DM; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Eshleman JR; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Lotan TL; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Antonarakis ES; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. |
| Source: | The oncologist [Oncologist] 2021 Feb; Vol. 26 (2), pp. e270-e278. Date of Electronic Publication: 2020 Dec 03. |
| Publication Type: | Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
